Unresectable or metastatic melanoma with disease progression following treatment with ipilimumab and, in BRAF V600 mutation–positive patients after treatment with a BRAF inhibitor (NCT01295827; 2014). This evidence concerns the gene BRAF and metastatic melanoma.